Treatment of hepatocellular carcinoma with child-Pugh C cirrhosis

Kazuhiro Nouso, Norihiro Kokudo, Masatoshi Tanaka, Ryoko Kuromatsu, Hiroki Nishikawa, Hidenori Toyoda, Naoki Oishi, Kenji Kuwaki, Masashi Kusanaga, Takuki Sakaguchi, Zenichi Morise, Satoshi Kitai, Masatoshi Kudo

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: In most guidelines, no other interventional therapy but liver transplantation is recommended for the treatment of hepatocellular carcinoma (HCC) with Child-Pugh C cirrhosis (CP-C). However, in Japan, patients were sometimes treated with expectation of benefit. Summary: A workshop was conducted to explore the state of treatments for CP-C HCC in Japan. After the workshop, a questionnaire on therapies was given to the panelists. Clinical data of 769 patients with CP-C HCC from 8 hospitals as well as analyses of data collected by the Liver Cancer Study Group of Japan (LCSGJ) consisting of 1,344 CP-C HCC cases were presented. Patients who underwent liver transplantation were excluded. In total, 424 out of the 769 patients (55.1%) from the 8 hospitals and 537 out of 828 CP-C HCC cases (64.8%) from the LCSGJ data received interventional therapies, such as local ablation and transcatheter arterial chemoembolization. All panelists agreed that there was a subgroup of CP-C patients who benefitted from the locoregional therapies. The major goals for the therapies were to prevent HCC rupture and avoid obstruction of major vessels by tumor growth, which can lead to a sudden deterioration of the patients' condition. Patient liver function and tumor stage are both important factors for the decision to undergo treatment; however, the inclusion criteria for the treatments varied among the centers. Key Message: There exists a subgroup of CP-C patients who benefit from interventions for HCC.

Original languageEnglish
Pages (from-to)99-103
Number of pages5
JournalOncology
Volume87
DOIs
Publication statusPublished - Apr 20 2014

Fingerprint

Hepatocellular Carcinoma
Fibrosis
Japan
Therapeutics
Liver Neoplasms
Liver Transplantation
Education
Rupture
Neoplasms
Guidelines
Liver
Growth

Keywords

  • Child-Pugh C cirrhosis
  • Hepatocellular carcinoma
  • Liver transplantation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Nouso, K., Kokudo, N., Tanaka, M., Kuromatsu, R., Nishikawa, H., Toyoda, H., ... Kudo, M. (2014). Treatment of hepatocellular carcinoma with child-Pugh C cirrhosis. Oncology, 87, 99-103. https://doi.org/10.1159/000368152

Treatment of hepatocellular carcinoma with child-Pugh C cirrhosis. / Nouso, Kazuhiro; Kokudo, Norihiro; Tanaka, Masatoshi; Kuromatsu, Ryoko; Nishikawa, Hiroki; Toyoda, Hidenori; Oishi, Naoki; Kuwaki, Kenji; Kusanaga, Masashi; Sakaguchi, Takuki; Morise, Zenichi; Kitai, Satoshi; Kudo, Masatoshi.

In: Oncology, Vol. 87, 20.04.2014, p. 99-103.

Research output: Contribution to journalArticle

Nouso, K, Kokudo, N, Tanaka, M, Kuromatsu, R, Nishikawa, H, Toyoda, H, Oishi, N, Kuwaki, K, Kusanaga, M, Sakaguchi, T, Morise, Z, Kitai, S & Kudo, M 2014, 'Treatment of hepatocellular carcinoma with child-Pugh C cirrhosis', Oncology, vol. 87, pp. 99-103. https://doi.org/10.1159/000368152
Nouso K, Kokudo N, Tanaka M, Kuromatsu R, Nishikawa H, Toyoda H et al. Treatment of hepatocellular carcinoma with child-Pugh C cirrhosis. Oncology. 2014 Apr 20;87:99-103. https://doi.org/10.1159/000368152
Nouso, Kazuhiro ; Kokudo, Norihiro ; Tanaka, Masatoshi ; Kuromatsu, Ryoko ; Nishikawa, Hiroki ; Toyoda, Hidenori ; Oishi, Naoki ; Kuwaki, Kenji ; Kusanaga, Masashi ; Sakaguchi, Takuki ; Morise, Zenichi ; Kitai, Satoshi ; Kudo, Masatoshi. / Treatment of hepatocellular carcinoma with child-Pugh C cirrhosis. In: Oncology. 2014 ; Vol. 87. pp. 99-103.
@article{fada1ae01daf418d8341bae171e372c5,
title = "Treatment of hepatocellular carcinoma with child-Pugh C cirrhosis",
abstract = "Background: In most guidelines, no other interventional therapy but liver transplantation is recommended for the treatment of hepatocellular carcinoma (HCC) with Child-Pugh C cirrhosis (CP-C). However, in Japan, patients were sometimes treated with expectation of benefit. Summary: A workshop was conducted to explore the state of treatments for CP-C HCC in Japan. After the workshop, a questionnaire on therapies was given to the panelists. Clinical data of 769 patients with CP-C HCC from 8 hospitals as well as analyses of data collected by the Liver Cancer Study Group of Japan (LCSGJ) consisting of 1,344 CP-C HCC cases were presented. Patients who underwent liver transplantation were excluded. In total, 424 out of the 769 patients (55.1{\%}) from the 8 hospitals and 537 out of 828 CP-C HCC cases (64.8{\%}) from the LCSGJ data received interventional therapies, such as local ablation and transcatheter arterial chemoembolization. All panelists agreed that there was a subgroup of CP-C patients who benefitted from the locoregional therapies. The major goals for the therapies were to prevent HCC rupture and avoid obstruction of major vessels by tumor growth, which can lead to a sudden deterioration of the patients' condition. Patient liver function and tumor stage are both important factors for the decision to undergo treatment; however, the inclusion criteria for the treatments varied among the centers. Key Message: There exists a subgroup of CP-C patients who benefit from interventions for HCC.",
keywords = "Child-Pugh C cirrhosis, Hepatocellular carcinoma, Liver transplantation",
author = "Kazuhiro Nouso and Norihiro Kokudo and Masatoshi Tanaka and Ryoko Kuromatsu and Hiroki Nishikawa and Hidenori Toyoda and Naoki Oishi and Kenji Kuwaki and Masashi Kusanaga and Takuki Sakaguchi and Zenichi Morise and Satoshi Kitai and Masatoshi Kudo",
year = "2014",
month = "4",
day = "20",
doi = "10.1159/000368152",
language = "English",
volume = "87",
pages = "99--103",
journal = "Oncology",
issn = "0030-2414",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Treatment of hepatocellular carcinoma with child-Pugh C cirrhosis

AU - Nouso, Kazuhiro

AU - Kokudo, Norihiro

AU - Tanaka, Masatoshi

AU - Kuromatsu, Ryoko

AU - Nishikawa, Hiroki

AU - Toyoda, Hidenori

AU - Oishi, Naoki

AU - Kuwaki, Kenji

AU - Kusanaga, Masashi

AU - Sakaguchi, Takuki

AU - Morise, Zenichi

AU - Kitai, Satoshi

AU - Kudo, Masatoshi

PY - 2014/4/20

Y1 - 2014/4/20

N2 - Background: In most guidelines, no other interventional therapy but liver transplantation is recommended for the treatment of hepatocellular carcinoma (HCC) with Child-Pugh C cirrhosis (CP-C). However, in Japan, patients were sometimes treated with expectation of benefit. Summary: A workshop was conducted to explore the state of treatments for CP-C HCC in Japan. After the workshop, a questionnaire on therapies was given to the panelists. Clinical data of 769 patients with CP-C HCC from 8 hospitals as well as analyses of data collected by the Liver Cancer Study Group of Japan (LCSGJ) consisting of 1,344 CP-C HCC cases were presented. Patients who underwent liver transplantation were excluded. In total, 424 out of the 769 patients (55.1%) from the 8 hospitals and 537 out of 828 CP-C HCC cases (64.8%) from the LCSGJ data received interventional therapies, such as local ablation and transcatheter arterial chemoembolization. All panelists agreed that there was a subgroup of CP-C patients who benefitted from the locoregional therapies. The major goals for the therapies were to prevent HCC rupture and avoid obstruction of major vessels by tumor growth, which can lead to a sudden deterioration of the patients' condition. Patient liver function and tumor stage are both important factors for the decision to undergo treatment; however, the inclusion criteria for the treatments varied among the centers. Key Message: There exists a subgroup of CP-C patients who benefit from interventions for HCC.

AB - Background: In most guidelines, no other interventional therapy but liver transplantation is recommended for the treatment of hepatocellular carcinoma (HCC) with Child-Pugh C cirrhosis (CP-C). However, in Japan, patients were sometimes treated with expectation of benefit. Summary: A workshop was conducted to explore the state of treatments for CP-C HCC in Japan. After the workshop, a questionnaire on therapies was given to the panelists. Clinical data of 769 patients with CP-C HCC from 8 hospitals as well as analyses of data collected by the Liver Cancer Study Group of Japan (LCSGJ) consisting of 1,344 CP-C HCC cases were presented. Patients who underwent liver transplantation were excluded. In total, 424 out of the 769 patients (55.1%) from the 8 hospitals and 537 out of 828 CP-C HCC cases (64.8%) from the LCSGJ data received interventional therapies, such as local ablation and transcatheter arterial chemoembolization. All panelists agreed that there was a subgroup of CP-C patients who benefitted from the locoregional therapies. The major goals for the therapies were to prevent HCC rupture and avoid obstruction of major vessels by tumor growth, which can lead to a sudden deterioration of the patients' condition. Patient liver function and tumor stage are both important factors for the decision to undergo treatment; however, the inclusion criteria for the treatments varied among the centers. Key Message: There exists a subgroup of CP-C patients who benefit from interventions for HCC.

KW - Child-Pugh C cirrhosis

KW - Hepatocellular carcinoma

KW - Liver transplantation

UR - http://www.scopus.com/inward/record.url?scp=84922481443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922481443&partnerID=8YFLogxK

U2 - 10.1159/000368152

DO - 10.1159/000368152

M3 - Article

C2 - 25427740

AN - SCOPUS:84922481443

VL - 87

SP - 99

EP - 103

JO - Oncology

JF - Oncology

SN - 0030-2414

ER -